Table 1.
Demographics of the patient population undergoing TP biopsy
| Variable | Value |
|---|---|
| Number of patients | 98 |
| Age, years, median (IQR) | 64.5 (50–72) |
| PSA level, ng/mL, median (IQR) | 7.53 (4.79–13.7) |
| Prostate volume, mL, median (IQR) | 51 (40–68.7) |
| Indication for biopsy | 93% rise in PSA, 6% AS |
| History of TURP, n | 17 |
| On 5α-reductase inhibitors, n | 10 |
| Size of the dominant lesion, cm, median (range) | 1 (0.7–1.5) |
| Clinical stage, n (%) | |
| cT1c | 52 (53.1) |
| cT2a | 43 (44.3) |
| cT2b | 2 (2) |
| ≥cT2c | 0 (0) |
| cTx | 1 (1) |
| PI-RADS scores of MRI targets, n (%) | |
| 3 | 27 (21.7) |
| 4 | 71 (57.2) |
| 5 | 26 (20.9) |
| Number of MRI targets per patient, median (IQR) | 1 (1–2) |
| Highest overall GG, n (%) | |
| No PCa | 39 (39.8) |
| GG1 | 11 (11.2) |
| GG2 | 15 (15.3) |
| GG3 | 13 (13.3) |
| GG4 | 5 (5.1) |
| GG5 | 12 (12.2) |